AMRI licenses CRISPR gene editing tech from Broad Institute

Contract research and manufacturing firm AMRI ($AMRI) has signed a deal with a pioneer of gene editing, the Broad Institute of MIT and Harvard, to get its hands on the hot ticket of CRISPR-Cas9.

The highly sought-after tech, which could see the first-ever in-human trials begin this year in China and the U.S., is used to edit genes by leveraging an RNA guide molecule to enter into specific cells.

A protein called Cas9 then attaches to the DNA and essentially cuts it, all of which either gets rid of, completely removes or replaces a gene with a better strand of DNA. A host of diseases could be treated with this approach, with cancer likely to be the first target in the clinic.

Whitepaper Download

Reducing the Complexity and Costs of Channel Planning and Logistics

How can you make the process of bringing your product to market less complex while also reducing costs? This Whitepaper identifies opportunities to simplify channel strategies for biopharma companies, their customers and patients. Discover how you can deliver savings and innovation to your business.

AMRI has a non-exclusive license with the Broad Institute to use its tech as both an offering to R&D-led firms as well as for its own internal research. Financial terms were not disclosed.

“While many people know CRISPR for its potential to edit defective genes to cure disease, there are a range of other applications in drug discovery for which CRISPR has significant utility that are critical to our customers' R&D projects, notably drug target assessment and in vitro model development for lead discovery and optimization,” said Christopher Conway, SVP of discovery and development services at AMRI.

“We are committed to continue to build our services offerings so that we stay in the leading position with important technologies such as CRISPR to enhance the success of our customers' programs.”

AMRI has been on something of a deal spree in 2016, including in May buying up Italian API specialist Euticals for $358 million in order to expand its manufacturing footprint and European reach.

In February, it saw total revenue for 2015 hit $402.3 million--an eye-watering increase of 45% compared with total revenue of $276.6 million for the same period in 2014. This latest deal is set to expand its research offering, which it hopes will beef up its appeal to life science companies.

- check out the release

Related Articles:
AMRI to acquire Euticals in a $358M deal, beefing up API offering
CRISPR patent battle heats up as new email disputes Zhang’s claims
China to pip U.S. researchers to the post on first CRISPR trial

Suggested Articles

The clinical testing giant LabCorp will now begin rolling out a blood test for lung cancer developed by Resolution Bioscience.

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

Cognoa aims to equip pediatricians with an AI-powered app that can spot the signs of autism, allowing them to diagnose in the doctor's office.